



Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Meyers, Rachel E., et al.  
Application No.: 10/001,851 Group No.: 1635  
Filed: November 20, 2001 Examiner: Schultz, James  
For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES  
THEREFOR

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

**OR**

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

  
\_\_\_\_\_  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: October 5, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)**

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

2.  The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).
- Applicant believes no fee is due in connection with this submission.

Fee due \$180.00

**METHOD OF PAYMENT OF FEE**


3.  Attached is a check in the amount of \$\_\_\_\_\_.
- Charge Account No. 501668 in the amount of \$180.00.
- A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

October 5, 2004

**MILLENNIUM PHARMACEUTICALS, INC.**

By Mario Cloutier  
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820



Practitioner's Docket No. **MPI00-459P1RM (formerly 10147-56U1)**

**PATENT**

OCT 12 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant's application of: Meyers, Rachel E., et al

Application No.: 10/001,851

Group No.: 1635

Filed: November 20, 2001

Examiner: Schultz, James

For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES  
THEREFOR

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1.  Preliminary Statements;
2.  Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449);
3.  Copies of Listed Information Items Accompanying This Statement (AB, CA-CZ)

10/13/2004 HGUTEMAI 00000012 501668 10001851

01 FC:1806 180.00 DA

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

- with sufficient postage as first class mail.

**37 C.F.R. SECTION 1.10\***

- as "Express Mail Post Office to Address"  
Mailing Label No.

**TRANSMISSION**

- transmitted by facsimile to the Patent and Trademark Office.

**Signature**

  
Sean Hunziker  
(type or print name of person certifying)

Date: October 5, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)**

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

October 5, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By: Mario Cloutier  
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820

Please type a plus sign (+) inside this box →  +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>OCT 1 2 2004 U.S. PATENT AND TRADEMARK OFFICE RECEIVED BY MAIL</b>	<b>Complete if Known</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
Sheet	1	of	1
		Attorney Docket Number	MPI00-459P1RM

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup> (if known) Kind Code <sup>5</sup>				

Examiner Signature		Date Considered	

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	1	of	4	Application Number	10/001,851
				Filing Date	November 20, 2001
				First Named Inventor	Rachel E. Meyers, et al.
				Group Art Unit	1635
				Examiner Name	James Schultz
				Attorney Docket Number	MPI00-459PIRM

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY3 (gly-3) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031833.			T <sup>2</sup>
	CB	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY4 (gly-4) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031834.			
	CC	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5a (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031835.			
	CD	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5b (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031836.			
	CE	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY5c (gly-5) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031837.			
	CF	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6a (gly-6) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031838.			
	CG	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6b mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031839.			
	CH	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase GLY6c (gly-6) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031840.			
	CI	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY7 (gly-7) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031841.			
	CJ	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY8 (gly-8) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031842.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/001,851
				Filing Date	November 20, 2001
				First Named Inventor	Rachel E. Meyers, et al.
				Group Art Unit	1635
				Examiner Name	James Schultz
				Attorney Docket Number	MPI00-459PIRM
Sheet	2	of	4		

OCT 12 2004  
SEARCHED INDEXED  
SERIALIZED FILED  
U.S. PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			
	CK	Hagen, F.K., et. al., "Caenorhabditis Elegans UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Homolog GLY9 (gly-9) mRNA, Complete Cds", April 15, 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AF031843.			T <sup>2</sup>
	CL	Isogai, T., et. al., "Homo Sapiens cDNA FLJ13720 fis, Clone PLACE2000438, Weakly Similar to Polypeptide N-Acetylgalactosaminyltransferase (EC 2.4.1.41)", January 30, 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AK023782.			
	CM	Sugano, S., et. al., "Homo Sapiens cDNA: FLJ21803 fis, Clone HEP00738", September 13, 2003 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AK025456.			
	CN	NCBI Annotation Project, "Homo Sapiens KIAA0266 Gene Product (KIAA0266), mRNA", October 16, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. XM_012288.			
	CO	"Hypothetical Protein XP_012288 [Homo Sapiens], October 16, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. XP_012288.			
	CP	Homa, F.L., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc Transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created November 1, 1995 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q07537.			
	CQ	Meurer, J.A., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 1, 1996 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q10472.			
	CR	Hagen, F.K., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 1, 1996 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q10473.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
Sheet	3	of	4
		Application Number	10/001,851
		Filing Date	November 20, 2001
		First Named Inventor	Rachel E. Meyers, et al.
		Group Art Unit	1635
		Examiner Name	James Schultz
		Attorney Docket Number	MPI00-459P1RM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		
	CS	Bennett, E.P., et al., "Polypeptide N-Acetylgalactosaminyltransferase 3 (Protein-UDP Acetylgalactosaminyltransferase 3) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 3) (Polypeptide GalNAc transferase 3) (GalNAc-T3) (pp-GaNTase 3)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q14435.		T <sup>2</sup>
	CT	Hagen, F.K., et al., "Probable N-Acetylgalactosaminyltransferase 9 (Protein-UDP Acetylgalactosaminyltransferase 9) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 9) (pp-GaNTase 9)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q9U2C4.		
	CU	Adams, M.D., et al., "Polypeptide N-Acetylgalactosaminyltransferase 8 (Protein-UDP Acetylgalactosaminyltransferase 8) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 8) (pp-GaNTase 8)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q9VUT6.		
	CV	Hagen, F.K., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1)," created October 16, 2001 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q08912.		
	CW	Yoshida, A., et al., "Polypeptide N-Acetylgalactosaminyltransferase 1 (Protein-UDP Acetylgalactosaminyltransferase 1) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 1) (Polypeptide GalNAc transferase 1) (GalNAc-T1) (pp-GaNTase 1) [Contains: Polypeptide N-Acetylgalactosaminyltransferase 1, Soluble Form]," created October 16, 2001 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 4, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q29121.		
	CX	Schwientek, T., et al., "Polypeptide N-Acetylgalactosaminyltransferase 11 (Protein-UDP Acetylgalactosaminyltransferase 11) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 11) (Polypeptide GalNAc transferase 11) (GalNAc-T11) (pp-GaNTase 11)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q8NCW6.		
	CY	Adams, M.D., et al., "Polypeptide N-Acetylgalactosaminyltransferase 2 (Protein-UDP Acetylgalactosaminyltransferase 2) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 2) (pp-GaNTase 2)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q6WV19.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/001,851
				Filing Date	November 20, 2001
				First Named Inventor	Rachel E. Meyers, et al..
				Group Art Unit	1635
				Examiner Name	James Schultz
Sheet	4	of	4	Attorney Docket Number	MPI00-459PIRM

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T <sup>2</sup>
	CZ	Durbin, R., "Putative Polypeptide N-Acetylgalactosaminyltransferase 11 (Protein-UDP Acetylgalactosaminyltransferase 11) (UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 11) (pp-GaNTase 11)," created October 1, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2004]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . Swiss Prot Accession No. Q7K755.		

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.